Topic
AI Capex Research
Current research indicates that AI infrastructure demand remains a primary driver for equity market strength, contributing significantly to a 26% year-over-year earnings growth in Q1 2026. This momentum has prompted revisions to market targets, with the S&P 500 projected to reach 8,000, supported by software gains and hardware innovations like Nvidia’s RTX Spark chip. Beyond mega-cap tech, AI-related capital expenditure is fostering a turnaround in small-cap equities and driving renewed M&A activity within the sector. The capital commitment to this space is further highlighted by high-profile moves such as Anthropic’s IPO filing, even as broader markets face headwinds from sticky inflation and headline PCE at 3.8%. Despite these macroeconomic pressures and rising energy costs, institutional flows remain concentrated in US large-cap products that capture AI growth. Ultimately, the research suggests that while inflationary risks persist, the secular trend of AI capex continues to underpin global equity sentiment and valuation expansions.
4191 reports available
All reports
Page 175 of 175
What Matters Today: CTAs, Pensions, Software Rally, and Potential Growth
Goldman Sachs · Apr 23, 2026
The New Inflation Regime
TS Lombard · Apr 23, 2026
GS Morning Update
Goldman Sachs · Apr 23, 2026
Equity Positioning and Key Levels
Goldman Sachs · Apr 13, 2026
Investment Strategy Quarterly
Raymond James · Apr 1, 2026
March and Q1 2026 Performance Review
Deutsche Bank · Apr 1, 2026
Markets and Macro
Goldman Sachs · Mar 29, 2026
Good Morning Mail
Goldman Sachs · Mar 25, 2026
Sentiment Positioning Late Cycle Tightening and Long Term Oil
Goldman Sachs International · Mar 14, 2026
Global Equities Call
Goldman Sachs · Mar 10, 2026
From Geopolitical Shocks To Structural Repricing
UBS · Mar 1, 2026
TMT Special Sales: Nvidia and Indra Beat, WPP Strategy, and Tech Conference Wrap
Goldman Sachs · Feb 26, 2026
Tactical Short: Expensive Defensives and Staples
Goldman Sachs & Co. LLC · Feb 20, 2026
When Tangible Wins
Goldman Sachs · Feb 20, 2026
Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals
William Blair · Jan 8, 2026